<DOC>
	<DOC>NCT01179048</DOC>
	<brief_summary>This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease HbA1c: 7.0% or above Antidiabetic drug naive or treated with one or more oral antidiabetic drugs (OADs) or treated with human NPH insulin or longacting insulin analogue or premixed insulin, alone or in combination with OAD(s) Type 1 diabetes Use of a glucagonlike peptide1 (GLP1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP4) inhibitor within the 3 months prior to screening (trial start) Use of insulin other than human NPH insulin or longacting insulin analogue or premixed insulin within 3 months prior to screening. Shortterm use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>